Abstract: The invention provides an anti-proliferative composition comprising a non-peptide analog of the C-terminal isoleucine-arginine (IR) tail motif of an activator of an anaphase promoting complex (APC). The invention further provides methods of inhibiting the ubiquitination activity of the APC by administering compositions of the invention.

Abstract: A product that includes a bioadhesive treatment solution for prevention of infectious diseases in the urinary tract of a female is provided. The product includes a polysaccharide. The product is positioned over the urinary tract of a female to act as a barrier against infectious transfer. A method for applying the product and a method for making the product are also disclosed.

Abstract: A product that includes a bioadhesive treatment solution for prevention of infectious diseases in the urinary tract of a female is provided. The product includes a polysaccharide. The product is positioned over the urinary tract of a female to act as a barrier against infectious transfer. A method for applying the product and a method for making the product are also disclosed.

Abstract: The invention provides an anti-proliferative composition comprising a non-peptide analog of the C-terminal isoleucine-arginine (IR) tail motif of an activator of an anaphase promoting complex (APC). The invention further provides methods of inhibing the ubiquitination activity of the APC by administering compositions of the invention.

Abstract: The technology described herein provides methods for addressing obesity by introducing a device into the stomach. Embodiments of a device for treating obesity may comprise a shaped membrane construct that contains a swellable material. The construct may be contained within a capsule which is ingested by a patient. When the capsule dissolves in the stomach, the gastric secretions may diffuse through the membrane and spontaneously swell the internal material, which swells and stiffens the construct sufficiently to create a sensation of satiety by both filling gastric volume and by distending the walls of the stomach. The volume of the construct may be sufficient to prevent passage through the pyloric sphincter. After a set period of time or after the administration of a degradation formulation, the device may structurally degrade to allow passage through the pyloric sphincter and eventual passage from the body.